Aficamten
As of the edition of 20 October 2026, Aficamten is a small molecule: marketed, first approved in 2025 (US); acts on MYH7; US protection ends in 2039.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2026
- Kind
- Small molecule
- Brand name
- Myqorzo
- First approved
- 19 December 2025 (US)
- Approvals on record
- 5 in 2 regions
- Holder of the most recent approval
- Cytokinetics; 2 holders in all
- Registered trials
- 12, 0 stopped early
- Disease areas
- Heart and blood vessels
US protection
US protection ends in 2039.
The last listed US drug-substance patent ends in 2039. The application that gives this date is held by Cytokinetics.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product8 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 8 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Aficamten.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| MYH7 | Myosin-7 | P12883 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 |
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 3 | 7 | 3 | 4 | 0 |
| Phase 4 | 1 | 0 | 1 | 0 |
| All trials | 12 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Cytokinetics | Originator, Applicant and Lead sponsor of trials | 2018 to now |